Feeling Flat on a GLP-1? What Doctors Know So Far
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Some people on a GLP-1 say the drug took more than their appetite. Food got quiet. So did music, hobbies, and friends. Doctors have a word for this: anhedonia. It means you stop feeling pleasure from things you used to enjoy. A few doctors are now writing about it. We read what they wrote and what the research says. The short answer: it's real for some people, it's rare as far as anyone knows, and it tends to get better on a lower dose.
Who This Helps
You might be on a GLP-1 and feel less like yourself. Or you might be thinking about starting one and saw a scary headline. Either way, this is for you. We wrote about the mood side of these drugs in May. New reports have come out since, so this is the update.
What has actually been seen
Less than you might think. The main report is a case series of three women (Obesity Pillars). All three were on the top dose of tirzepatide, 15 mg a week. All three lost weight. Two told their doctors they felt flat and had lost interest in things they liked. The third didn't report anything at first, but her drive picked up after a pause and a restart at a lower dose. One of the three had a history of depression.
The doctors lowered their dose. All three improved. The one with prior depression also needed an antidepressant called bupropion. Those are the only published cases on tirzepatide. Three people.
The lead author and a University of Florida researcher say they are gathering about 100 more cases (MindSite News). Those aren't published yet, so no one has checked them.
There is one more clue. A review of side effect reports sent to the FDA found more reports of anhedonia for GLP-1 users than for people on other diabetes and weight drugs (Pharmaceuticals). It also found more reports of depression and suicidal thoughts. But these are reports people chose to send in. They don't show how common anything is. They don't prove the drug caused it. And the people on the other drugs were older, which skews the comparison.
How common is it
Nobody knows. There is no study that counted. Dr. Spencer Nadolsky, who wrote up the three cases and runs a telehealth clinic, calls it not very common (Gizmodo). That's his view, not a measurement. Dr. Josh Neal at MUSC says most big trials never asked about it, so they could not have found it (MUSC). Fair point. You don't find what you don't look for.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Why it might happen
GLP-1 drugs work partly in the brain. They quiet the part that makes food feel like a reward. Many people call this losing their food noise. The theory is simple: the same switch that turns down food might turn down other rewards too.
In mice, this seems to happen. In one study not yet peer reviewed, mice on semaglutide ran less on their wheels and worked less hard to get to them (bioRxiv). In people, we know the drugs cut food cravings and that people on them drink less alcohol. No one's shown they dull pleasure in general. Dr. Neal put it well. The biology is plausible, he said, but we have not seen it in the data.
Is this like SSRIs
People ask this because SSRI antidepressants can cause something similar. It is called emotional blunting. You feel less sad, but also less happy. One survey found 46% of people on antidepressants felt some of this (Journal of Affective Disorders). A review found it may be tied to dose, and that most doctors respond by lowering the dose or switching drugs (Acta Neuropsychiatrica).
The GLP-1 reports sound a lot like that. Lower the dose and it often lifts. Bupropion shows up in both stories too, as a drug that blunts less and as a drug one patient was given. But no study has compared the two side by side. The link is a doctor's hunch, not a finding. One more thing muddies it: many people take both drugs at once. Hard to tell which one did what.
What the big studies say
Now the big picture. In January 2026 the FDA looked at 91 trials with over 107,000 people. It found no higher risk of suicidal thoughts, depression, anxiety, or irritability. It asked the drug makers to take the old suicide warning off the labels, and Zepbound's label shows it removed (FDA).
A review of 80 trials found the same. People on GLP-1s did not have more mental health problems. If anything, they scored a little better on quality of life (JAMA Psychiatry). Most of those trials were of semaglutide and liraglutide, not the top dose of tirzepatide the three cases were on. And many of the same trials fed into the FDA review, so these aren't two separate checks.
In Sweden, researchers followed 95,000 people with depression or anxiety who were on diabetes drugs. About 22,000 used a GLP-1. During the months people took semaglutide, they were 42% less likely to miss work or go to the hospital for mental health than during months they didn't (Karolinska Institutet). That's not a trial, so it can't prove cause. But it points the other way from the scary headlines.
None of these studies asked about anhedonia directly. So they don't rule it out. They do show that for most people, mood holds up or improves.
Should you not take a GLP-1 because of this
None of the doctors in these reports say that. Dr. Nadolsky said this should not stop people from trying the drug if they need it, but this is always something you should discuss with a clinician who has your specific health history rather than following something on the internet. It is not very common, he said, and can be managed with dose changes, with or without an antidepressant. He also said it needs to be checked in proper studies. A Stanford professor, Keith Humphreys, warned against getting ahead of the data. We don't know how rare this is, he said, or whether it goes away if you simply stop the drug (Washington Times).
So where does that leave you? It's a real thing some people report. It's probably rare. It seems to respond to a dose change. And those big trials found no mood harm for most people.
What you can do
These come from doctors quoted in the coverage. They are common sense, not proven treatments.
- Notice it. Ask yourself if things you used to enjoy still feel good. Dr. Neal says studies would have to ask about this directly to find it. The same goes for you.
- Track it against your dose. Did the flat feeling start after you went up a step? That's useful for your doctor to know.
- Check the basics. Are you eating enough? Enough protein? Sleeping? Moving? Eating too little can make anyone feel flat.
- Tell your prescriber. In the three cases, a lower dose fixed it. That takes the solution from 'stop it entirely' to 'dosage tweak'.
- Don't just stop. The FDA's advice is to keep taking the drug as prescribed and talk to your doctor about any concerns (FDA). Our piece on what happens when you stop covers why.
Final Takeaway
Three patients felt flat on a high dose and improved on a lower one, one with help from an antidepressant. That's the published record on tirzepatide. Doctors say they've seen more, but those cases aren't written up yet. The big studies, with over 100,000 people, show no mood harm. If you feel less like yourself, say so. Your prescriber needs to hear it.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Is anhedonia a known side effect of GLP-1s?
It's not on any drug label. The published evidence is a report of three patients. Side effect databases show some reports, but those cannot show how common it is.
Does it go away?
In the three published cases, yes, after the dose was lowered, and in one case with an antidepressant added. The lead author says cases he sees tend to lift within weeks (MindSite News). No study has tested this.
Which drugs cause it?
The three cases were all on tirzepatide, the drug in Zepbound. Reports also mention semaglutide, which is in Wegovy and Ozempic. No one has compared them.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
FDA's September 2026 warning letter has two separate sets of findings. See which one affects patients and which is a legal dispute.
Employers are dropping GLP-1 coverage. See how to check any plan's drug list before open enrollment closes, and what the conditions mean.
Tirzepatide can make the birth control pill less reliable for 4 weeks after each dose change. Semaglutide doesn't. See what your label says.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.